Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s358, 2024. DOI: 10.25251/skin.8.supp.358. Disponível em: https://skin.dermsquared.com/skin/article/view/2653. Acesso em: 4 apr. 2025.